The project is focused on the inhibition of serine metabolism and folic acid cycle using small molecule inhibitors with the proven selective mechanism of action. Up-to-date research has allowed identification of key points of metabolism, protein molecular targets and markers of sensitivity and selection of patients. Based on this knowledge, we design and develop new active molecules allowing a targeted therapeutic approach. These molecules in addition to greater efficiency, provided by a personalized therapy, will be characterized by safety of use due to the specificity of action. Molecular targets selected for the project give a good chance of obtaining a first-in-class drug.